Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CRIS
CRIS logo

CRIS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Curis Inc (CRIS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.010
1 Day change
52 Week Range
3.180
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Curis Inc (CRIS) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are bearish, financial performance is weak, and there are no significant positive catalysts or trading signals to support a buy decision. Holding off on this investment until stronger signals or improved fundamentals emerge is recommended.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. The RSI is neutral at 40.627, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.063, with support at 0.981 and resistance at 1.144. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

  • NULL identified. No recent news, no significant trading trends from hedge funds or insiders, and no recent congress trading data.

Neutral/Negative Catalysts

  • Weak financial performance in Q3 2025 with declining net income (-23.41% YoY), EPS (-71.18% YoY), and gross margin (-31.34% YoY). Analysts have lowered price targets for the sector, and bearish technical indicators further weigh on the stock.

Financial Performance

In Q3 2025, revenue increased by 8.36% YoY to $3,176,000. However, net income dropped by 23.41% YoY to -$7,729,000, EPS fell by 71.18% YoY to -0.49, and gross margin decreased by 31.34% YoY to 71.66%. These figures indicate a challenging financial environment for the company.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have mixed views on the sector. Price targets for similar companies have been adjusted downward recently, reflecting cautious sentiment. While some analysts see potential recovery in 2026, there are no immediate catalysts for CRIS.

Wall Street analysts forecast CRIS stock price to rise
2 Analyst Rating
Wall Street analysts forecast CRIS stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.010
sliders
Low
5
Averages
11
High
17
Current: 1.010
sliders
Low
5
Averages
11
High
17
Evercore ISI
Outperform
downgrade
$40 -> $38
AI Analysis
2026-01-05
Reason
Evercore ISI
Price Target
$40 -> $38
AI Analysis
2026-01-05
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Caris Life Sciences to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Canaccord
Kyle Mikson
Hold
maintain
$28 -> $30
2025-12-22
Reason
Canaccord
Kyle Mikson
Price Target
$28 -> $30
2025-12-22
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Caris Life Sciences to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. They beleve Caris Life Sciences could be attractive with continued momentum or a material share price pullback.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CRIS
Unlock Now

People Also Watch